High Expression of Interleukin-2 Receptor Subunit Gamma Reveals Poor Prognosis in Human Gastric Cancer.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
10
2020
revised:
20
12
2020
accepted:
11
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
Precision medicine for gastric cancer (GC) is still an unsolved issue, because most available target drugs are not specifically designed for GC. Exploring novel signaling molecules with target value for GC is in urgent need. This study aimed to reveal that interleukin-2 receptor subunit gamma (IL2RG) is such a key molecule in human GC progression. GC tissues and paracancerous gastric tissues were collected from 7 patients (5 males and 2 females) during tumor radical excision surgery. These tissues were used to identify the differentially expressed genes (DEGs) with RNA-seq and serial bioinformatics analyses including Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, gene expression profiling interactive analysis (GEPIA), and survival analysis. RT-qPCR and western blotting were performed to compare the mRNA and protein expression levels of IL2RG between GC tissues and adjacent normal gastric tissues as well as between GC cell line SGC-7901 and normal gastric epithelial cell line GES-1. Results showed striking elevations of IL2RG both in the mRNA and protein levels in GC tissues and human gastric cancer SGC-7901 cell line compared, respectively, with the adjacent normal gastric tissues and normal GES-1 cells, and higher IL2RG expression was associated with lower survival. Analyses on the GSE29272 and GSE15459 datasets from Gene Expression Omnibus verified that IL2RG was highly expressed in GC patients and was associated with poor overall survival. In addition, molecular docking showed that a small molecule, resatorvid (TAK 242), might be an inhibitor of IL2RG. We conclude that IL2RG is overexpressed in advanced GC and is associated with low survival. IL2RG may serve as a biomarker of GC progression and poor prognosis.
Identifiants
pubmed: 33542731
doi: 10.1155/2021/6670834
pmc: PMC7843183
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6670834Informations de copyright
Copyright © 2021 De-Ping Wang et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Immunol Res. 2019 Dec;67(6):505-516
pubmed: 32026322
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Biol. 2014;15(12):550
pubmed: 25516281
Br J Cancer. 2016 Apr 12;114(8):855-62
pubmed: 27031850
BMC Cancer. 2012 Oct 15;12:475
pubmed: 23066954
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
Crit Rev Oncol Hematol. 2016 Nov;107:72-81
pubmed: 27823653
Nat Rev Immunol. 2009 Jul;9(7):480-90
pubmed: 19543225
Ann Oncol. 2012 Jan;23(1):28-36
pubmed: 21536659
PLoS Genet. 2009 Oct;5(10):e1000676
pubmed: 19798449
PLoS One. 2013 May 22;8(5):e63826
pubmed: 23717493
J Med Chem. 2005 Nov 17;48(23):7457-67
pubmed: 16279805
J Gastrointest Surg. 2001 Jan-Feb;5(1):81-90
pubmed: 11309652
Updates Surg. 2018 Jun;70(2):173-179
pubmed: 29946806
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Lancet Oncol. 2017 Mar;18(3):357-370
pubmed: 28163000
J Transl Med. 2011 Sep 26;9:162
pubmed: 21943235
Cancer Epidemiol. 2018 Jun;54:125-132
pubmed: 29727805
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4
pubmed: 18077471
Oncogene. 2013 May 23;32(21):2601-13
pubmed: 22869151
World J Gastroenterol. 2016 May 21;22(19):4619-25
pubmed: 27217694
J Gastric Cancer. 2016 Sep;16(3):182-190
pubmed: 27752396